Methodist Journal

IN THIS ISSUE

Lipids and Lipoproteins

Vol 15, Issue 1 (2019)


FEATURED GUEST EDITOR

ISSUE INTRO

Lipids and Cardiovascular Disease: Putting it All Together

See More
RECOGNITIONS

Guest Editors Henry Pownall and Antonio Gotto Offer Insight and Expertise on the topic of Lipids and Cardiovascular Disease

See More

REVIEW ARTICLES See More

Cholesterol: Can’t Live With It, Can’t Live Without It

How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)lines

Statins: Then and Now

Poststatin Lipid Therapeutics: A Review

HDL and Reverse Cholesterol Transport Biomarkers

Revisiting Reverse Cholesterol Transport in the Context of High-Density Lipoprotein Free Cholesterol Bioavailability

High-Density Lipoprotein Subspecies in Health and Human Disease: Focus on Type 2 Diabetes

Gene Delivery in Lipid Research and Therapies

CASE REPORTS See More

Device-Related Thrombus: A Reason for Concern?

Retained Coronary Balloon Requiring Emergent Open Surgical Retrieval: An Uncommon Complication Requiring Individualized Management Strategies

Loperamide Mimicking Brugada Pattern

Reversed Pulsus Paradoxus in Right Ventricular Failure

MUSEUM OF HMH MULTIMODALITY IMAGING CENTER See More

Transcatheter Embolization of a Persistent Vertical Vein: A Rare Cause of Left-to-Right Shunt and Right-Sided Heart Failure

CLINICAL PERSPECTIVES See More

EXCERPTA

Talking Statins with Antonio Gotto

POINTS TO REMEMBER

Lipids and Renal Disease

EXCERPTA

Addressing the Feedback Loop Between Depression, Diabetes, and Cardiovascular Disease

POINTS TO REMEMBER

The Kidney as an Endocrine Organ

EDITORIALS

Addressing the Underrepresentation of Women in Cardiology through Tangible Opportunities for Mentorship and Leadership

Vol 14, Issue 2 (2018)

Article Full Text

CLINICAL PERSPECTIVES

Redefining “Worth It” for CTO PCI

Jump to:
Article Citation:

Chang R. Redefining “Worth It” for CTO PCI. Methodist Debakey Cardiovasc J website. journal.houstonmethodist.org. July 9, 2018.



Keywords
chronic total occlusion  ,  percutaneous coronary intervention  ,  complete revascularization  ,  angina  ,  CAD  ,   interventional cardiology  ,   ischemia  ,   ischemic heart disease 

The utility of percutaneous coronary intervention for treating chronic total occlusion (CTO PCI) has been a subject of heated debate in the cardiovascular community for the last decade. CTO PCI is known—perhaps unfairly—for low success rates, questionable benefits, and a difficult, complex procedure, and many interventionalists prefer not to attempt it. Nevertheless, thanks to advances in technology and technique—and an expanding idea of what makes a procedure “worth it”—popular opinion appears to be shifting in CTO PCI’s favor.

Finding a Middle Ground

Alpesh Shah, M.D.

CTOs are blockages of coronary arteries that result from severe build-ups of fat or plaque and are a complication of coronary artery disease. Symptoms of CTO include shortness of breath, fatigue, or angina. Traditionally, physicians have treated patients with CTO surgically—CTO being one of the most common reasons for coronary artery bypass grafting (CABG) referral—or if surgery isn’t feasible, with medical therapy. However, even CABG is often unsuccessful at revascularizing the CTO, says Alpesh Shah, M.D., interventional cardiologist at Houston Methodist Hospital. Moreover, he says, many patients fall somewhere in between those two extremes, needing something less invasive and risky than surgery but more aggressive than medicine alone. For them, CTO PCI could be a game-changing option.

“On one end of the spectrum, we have patients who are very young and do not want to go through open heart surgery, but they are limited by their symptoms or quality of life. And on the other end, we have very sick patients who are not surgical candidates,” Shah says. “Should we subject the young patients to CABG surgery, [which may or may not completely bypass the CTO segment]? Are non-surgical candidates going to be limited to medical therapy and continue to have quality of life or angina issues? [In these cases, CTO PCI may be an excellent alternative].”

Defining Benefits

Whether or not CTO PCI offers definitive benefits has long been uncertain, as Shah explains in his recent review of CTO PCI.1 Although the procedure addresses many of the symptoms associated with CTO—including fatigue, dyspnea, ischemia, and left ventricular impairment—there is no proof that it improves survival in patients.1 CTO PCI is also more complex, requires more time, and is more expensive than routine PCI, and has lower overall success rate.1 Some believe that, if CTO PCI does not actually increase chances of survival, the procedure is not worth the higher risk of complications or significant investments in time and money.

That being said, even if CTO PCI doesn’t have survival benefit in terms of CTO correction, Shah encourages physicians to look ahead. Uncorrected CTOs are an independent predictor of death from other cardiac events, so removing or bypassing the blockage could potentially save the patient’s life if there is occlusion of other coronary arteries.

“We know that if patients who have a CTO in one artery develop an obstruction in another artery, their mortality rates are significantly higher. So, beyond symptoms and quality of life, one should also consider the possibility of that double jeopardy later on. That’s one reason we encourage our physicians to reach out to CTO operators early,” Shah says.

Complexities of CTO PCI

CTO PCI differs from standard PCI in a number of ways. In CTO PCI, the obvious challenge is getting across a completely blocked artery and creating a new channel.

“The more complex the technique, the higher the complication rates, especially at low volume centers,” Shah says. “There are several specialized techniques, such as antegrade wiring and retrograde wiring, [that CTO operators must learn]. Compared to a routine PCI, a CTO PCI has higher complication rates.”

Indeed, one of the difficulties with widespread adoption of CTO PCI is that not just any interventionalist can pick up the wires and get started. CTO PCI is a time-consuming, expensive procedure that requires operators to master a wide range of specialized tools and techniques, and the procedure’s success is uniquely tied to his or her skill and experience. The success rate exceeds 85% in the hands of an experienced physician.1 However, CTOs performed by inexperienced operator have much lower chances of success. For instance, Hannan et al.’s analysis of CTO PCI procedures in New York from 2009 to 2012 showed that operators who performed fewer than 9 CTO PCIs per year (half of all studied) had less than half the success of those who performed at least 48 annually (the top 25%).2 Moreover, according to Massachusetts General Hospital, only 1 to 2 percent of cardiac interventionalists in the United States are able to perform the entire range of CTO PCI procedures.3 Given this disparity in outcomes, the national average success rate (reported at around 59%)4 has little bearing on a given case’s outlook—but it does shed some light on why, historically, so few physicians have been keen to recommend CTO PCI.

Enhancing Training and Technology

In recent years, studies such as Hannan’s and registries like PROGRESS CTO are bringing the encouraging results of high-volume CTO PCI centers out of the shadows. Although high-volume, high-success centers such as Shah’s program at Houston Methodist are few and far between, those centers are preparing a new generation of fellows to tackle complex CTO PCI procedures.

“Large academic centers usually have one designated CTO expert who often can teach fellows the required skills. In those programs, fellows are often exposed to almost 100 CTOs, which prepares them well for the real world,” Shah says.

These fellows bring much needed experience and skills to the table just as recent advancements in technology are increasing the success rate of CTO PCI. Wire designs with higher crossing power, polymer-jacketed wires, and crossing catheters have all contributed to higher success rates. These advances, which reduce the likelihood of complications in CTO PCI, make the procedure a more attractive alternative to CABG.

Improving Patient Selection

Another factor making CTO PCI more favorable is improvements in patient selection. With better patient screening and the development of risk assessments such as the  PROGRESS CTO Score Calculator,6 physicians can now identify who is best suited for CABG, PCI, or medical therapy, hopefully avoiding the unsuccessful outcomes or complications that have historically plagued CTO interventions.

“Overall, we have gotten better at patient selection,” Shah says. “We work very closely with our cardiac surgeons to [evaluate] patients with complex anatomy, especially CTO vessels, to identify the right [procedure for each individual]. We weigh pros and cons of bypass surgery as well as a PCI.  At the same time, we collaborate with our heart failure doctors who have many patients with very advanced coronary artery disease, often with multiple CTOs.”

Redefining Success

Of course, determining whether or not a patient is physically qualified for CTO PCI is only part of the decision-making process; both patients and physicians must decide if the intervention is worthwhile. Without a clear survival benefit, “worthwhile” can be subjective. Although a patient may have severe symptoms that could be treated by CTO PCI, the procedure still has some risk for perforation and tamponade, donor vessel injury, myocardial infarction, and rarely, death.5 Furthermore, some physicians believe that alleviating symptoms is not enough of a benefit to outweigh the risks. However, for the patient, improvements in quality of life may make the procedure worth it.

“I think an important question is, what are the options for our patient?  Are they going to be limited to medical therapy but then continue to have quality of life or angina issues?” Shah says. “We’ve learned to ask our patients what their goals are. [If those goals are limited] by angina or shortness of breath, there’s very significant benefit of CTO PCI.”

In a field where survival is the ultimate goal, performing invasive (even minimally invasive) procedures for symptom improvement may challenge the traditional treatment paradigm. But for Shah, CTO PCI is an opportunity to change lives.

“For patients, It’s like somebody has gone in and replaced their knee and now they can walk and run marathons if they wish to,” Shah says. “I find this CTO PCI work most rewarding when it comes to patients’ gratitude. They come and hug me and thank me because they certainly see a change in their life.”

References
  1. Shah A. Chronic Total Occlusion Coronary Intervention: In Search of a Definitive Benefit. Methodist DeBakey Cardiovasc J. 2018;14(1):52-59.
  2. Hannan EL, Zhong Y, Jacobs AK, et al. Patients with chronic total occlusions undergoing percutaneous coronary interventions: characteristics, success, and outcomes. Circ Cardiovasc Interv. 2016 May;9(5):e003586.
  3. Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI) [Internet]. Massachusetts General Hospital. [cited 2018 June 3]. Available from: https://www.massgeneral.org/heartcenter/services/procedure.aspx?id=2308.
  4. Brilakis ES, Banerjee S, Karmpaliotis D, et al. Procedural outcomes of chronic total occlusion percutaneous coronary intervention: a report from the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv. 2015;8:245-53.
  5. Brilakis ES. Risks, Benefits of CTO PCI Must be Weighed [Internet]. Helio; May/June 2017 [cited 3018 June 2]. Available from: https://www.healio.com/cardiac-vascular-intervention/chronic-total-occlusion/news/print/cardiology-today-intervention/%7B22c451c8-77ee-4634-a642-fd4dac6eddb8%7D/risks-benefits-of-cto-pci-must-be-weighed.
  6. CTO scores. PROGRESS-CTO. http://www.progresscto.org/cto-scores. Accessed July 9, 2018.

Add Comments

Please login to dialogue with author.

Comments